ASH 2014: Phase Ib dose escalation trial of SAR650984 (anti-CD38 monoclonal antibody) in combination with lenalidomide and dexamethasone improves overall response rate and clinical benefit response in relapsed or refractory myeloma
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Thomas Martin (University of California San Francisco, San Francisco, CA) discusses a phase Ib dose esca... Author: EMJ Added: 12/09/2014 (Source: Oncology Tube)
Source: Oncology Tube - December 9, 2014 Category: Cancer & Oncology Source Type: podcasts

ASH12: New Myeloma Drug Works Better with Low-Dose Dexamethasone
Pomalidomide, an investigational third-generation immunomodulatory drug, was more effective when combined with low-dose dexamethasone than high-dose in a clinical trial presented at the annual meeting... Author: feeds Added: 09/04/2013 (Source: Oncology Tube)
Source: Oncology Tube - September 4, 2013 Category: Cancer & Oncology Source Type: podcasts

Cyclophosphamide lenalidomide and dexamethasone in newly diagnosed myeloma
Dr Annamaria Brioli talks to ecancer at the 18th EHA Congress in Stockholm, Sweden about two studies that examine the use of cyclophosphamide lenalidomide and dexamethasone in myeloma. The first st... Author: feeds Added: 08/30/2013 (Source: Oncology Tube)
Source: Oncology Tube - August 30, 2013 Category: Cancer & Oncology Source Type: podcasts